Results of the two incidence screenings in the National Lung Screening Trial

Abstract

Background: The National Lung Screening Trial was conducted to determine whether three annual screenings (rounds T0, T1, and T2) with low-dose helical computed tomography (CT), as compared with chest radiography, could reduce mortality from lung cancer. We present detailed findings from the first two incidence screenings (rounds T1 and T2).

Methods: We evaluated the rate of adherence of the participants to the screening protocol, the results of screening and downstream diagnostic tests, features of the lung-cancer cases, and first-line treatments, and we estimated the performance characteristics of both screening methods.

Results: At the T1 and T2 rounds, positive screening results were observed in 27.9% and 16.8% of participants in the low-dose CT group and in 6.2% and 5.0% of participants in the radiography group, respectively. In the low-dose CT group, the sensitivity was 94.4%, the specificity was 72.6%, the positive predictive value was 2.4%, and the negative predictive value was 99.9% at T1; at T2, the positive predictive value increased to 5.2%. In the radiography group, the sensitivity was 59.6%, the specificity was 94.1%, the positive predictive value was 4.4%, and the negative predictive value was 99.8% at T1; both the sensitivity and the positive predictive value increased at T2. Among lung cancers of known stage, 87 (47.5%) were stage IA and 57 (31.1%) were stage III or IV in the low-dose CT group at T1; in the radiography group, 31 (23.5%) were stage IA and 78 (59.1%) were stage III or IV at T1. These differences in stage distribution between groups persisted at T2.

Conclusions: Low-dose CT was more sensitive in detecting early-stage lung cancers, but its measured positive predictive value was lower than that of radiography. As compared with radiography, the two annual incidence screenings with low-dose CT resulted in a decrease in the number of advanced-stage cancers diagnosed and an increase in the number of early-stage lung cancers diagnosed. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.).

Figure 1. Randomization and Follow-up of the Study Participants.

Panel A shows randomization and follow-up for the T1 screening. During the T1 study year, 2 of 437 ineligible participants in the low-dose computed tomography (CT) group and 3 of 322 ineligible participants in the radiography group received a diagnosis of lung cancer (data not shown). Panel B shows randomization and follow-up for the T2 screening. During the T2 study year, 3 of 780 ineligible participants in the low-dose CT group and 4 of 622 ineligible participants in the radiography group received a diagnosis of lung cancer (data not shown).

Figure 1. Randomization and Follow-up of the Study Participants.

Panel A shows randomization and follow-up for the T1 screening. During the T1 study year, 2 of 437 ineligible participants in the low-dose computed tomography (CT) group and 3 of 322 ineligible participants in the radiography group received a diagnosis of lung cancer (data not shown). Panel B shows randomization and follow-up for the T2 screening. During the T2 study year, 3 of 780 ineligible participants in the low-dose CT group and 4 of 622 ineligible participants in the radiography group received a diagnosis of lung cancer (data not shown).